Explore 3 Stock Ideas & Industry Insights Download Free Report

Nexentis Technologies Inc.

Company price
2.4365 USD -0.13 ( 5.23%)
Last update at 2026-11-09T14:57:00Z
VOLUME
29406
Market Cap
2.08M
P/E
0.19

Momentum Score

…

Nexentis Technologies Inc., through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. It operates through two segments, Biotechnology Activity and Renewable Energy Projects. The company's pipeline includes MITOLINE, an algorithm used to perform multiple sequence/ structure pairwise alignments which could then be used for generating a 3D comparative model of potentially all mitochondrial carrier proteins; cloud-based computational chemistry platform; and novel in-vitro screening platforms; and advanced 3D NSCLC tumor spheroid systems.The company was formerly known as N2OFF, Inc. and changed its name to Nexentis Technologies Inc. in February 2026. Nexentis Technologies Inc. was incorporated in 2009 and is headquartered in Ness Ziona, Israel.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
2.29
Low
2.64
High
52 Week Price Range
1.28
Low
42.83
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
2.57
Dividend Yield
-
Revenue TTM
0.21M
Revenue Per Share
0.36
Gross Profit TTM
0.00M
Debt / Equity
0.06
ROE
-454.82%
Net Debt
-2.84M
ROCE
-18.44%
Diluted EPS TTM
7.48

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -3.61M -5.35M -7.26M -5.78M -4.87M
Minority interest 0.15M 0.15M 0.74M 0.04M 0.04M
Net income -4.00M -5.19M -6.52M -5.74M -4.82M
Selling general administrative 5.11M 3.99M 5.80M 5.28M 4.21M
Gross profit -0.08M 0.03M 0.19M 0.21M 0.24M
Reconciled depreciation 0.07M 0.02M 0.02M 0.05M 0.06M
Ebit -3.50M -4.05M -7.30M -5.71M -4.54M
Ebitda -3.42M -4.03M -7.28M -5.66M -4.48M
Depreciation and amortization 0.08M 0.02M 0.02M 0.05M 0.06M
Operating income -4.23M -4.05M -7.30M -5.71M -4.54M
Other operating expenses 4.23M 4.26M 7.56M 6.10M 4.98M
Interest expense 0.11M 0.10M 0.01M 0.01M 0.04M
Tax provision -0.02M 0.00M - - -
Interest income - 0.07M 0.07M 0.03M -
Net interest income -1.63M -0.12M 0.06M 0.02M -0.15M
Income tax expense -0.02M - - - -
Total revenue 0.00M 0.21M 0.26M 0.39M 0.44M
Total operating expenses 4.23M 4.08M 7.49M 5.92M 4.79M
Cost of revenue 0.08M 0.18M 0.08M 0.19M 0.19M
Total other income expense net 0.62M -1.30M 0.04M -0.07M -0.32M
Net income from continuing ops -3.60M -5.35M -7.26M -5.78M -4.87M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 20.41M 5.46M 7.24M 6.49M 7.60M
Intangible assets 5.15M - - - -
Other current assets 1.41M 0.49M 0.76M 0.25M 0.23M
Total liab 4.67M 0.89M 0.79M 0.75M 1.18M
Total stockholder equity 16.01M 4.75M 6.48M 5.85M 6.48M
Other current liab 0.68M 0.84M 0.69M 0.23M 0.34M
Common stock - 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -38.56M -34.55M -29.36M -22.84M -17.10M
Good will 6.29M 0.00M - - -
Cash 3.83M 2.21M 4.48M 5.75M 6.81M
Total current liabilities 1.43M 0.89M 0.78M 0.71M 0.93M
Net debt -2.84M -2.20M -4.42M -5.60M -6.58M
Short term debt 0.75M 0.01M 0.04M 0.07M 0.05M
Short long term debt 0.74M - - - 0.01M
Short long term debt total 0.99M 0.01M 0.05M 0.15M 0.23M
Other stockholder equity 54.60M 39.33M 35.87M 28.71M 23.61M
Total current assets 6.01M 3.40M 5.47M 6.27M 7.23M
Long term investments 2.74M 1.41M 1.66M 0.00M -
Short term investments 0.24M 0.31M 0.00M - -
Net receivables 0.53M 0.38M 0.11M 0.19M 0.17M
Long term debt 0.24M - - - -
Inventory - 0.02M 0.12M 0.08M 0.02M
Accounts payable 0.01M 0.05M 0.04M 0.42M 0.54M
Accumulated other comprehensive income -0.04M -0.03M -0.03M -0.03M -0.03M
Non currrent assets other 0.16M 0.24M - - 0.14M
Non current assets total 14.39M 2.06M 1.78M 0.22M 0.37M
Capital lease obligations 0.01M 0.01M 0.05M 0.11M 0.13M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 0.00M -0.22M 0.00M - -
Total cashflows from investing activities -3.23M -1.89M -1.52M -0.05M -0.08M
Net borrowings 1.38M -0.09M 0.00M -0.01M 0.23M
Total cash from financing activities 8.86M 3.05M 3.47M 4.09M 10.73M
Net income -4.16M -5.19M -6.52M -5.74M -4.82M
Change in cash 1.80M -2.27M -1.27M -1.06M 6.54M
Begin period cash flow 2.21M 4.48M 5.75M 6.81M 0.27M
End period cash flow 4.01M 2.21M 4.48M 5.75M 6.81M
Total cash from operating activities -3.81M -3.42M -3.23M -5.10M -4.10M
Issuance of capital stock 1.50M 0.00M 0.00M 4.10M 10.50M
Depreciation 0.07M 0.02M 0.02M 0.05M 0.06M
Other cashflows from investing activities -0.87M -0.66M - - -0.02M
Change to inventory 0.01M 0.10M -0.04M -0.06M -0.01M
Change to account receivables 0.01M -0.04M 0.09M -0.02M -0.02M
Other cashflows from financing activities 4.15M 3.13M 3.47M - -0.04M
Capital expenditures 0.01M 0.00M 0.00M 0.05M 0.07M
Change in working capital -0.10M 0.17M 0.29M -0.27M -0.05M
Stock based compensation 2.15M 0.75M 2.50M 0.94M 0.64M
Other non cash items -1.77M 1.59M 2.98M 0.86M 0.72M
Free cash flow -3.82M -3.42M -3.23M -5.15M -4.17M

Peer Comparison*

Sector: Basic Materials Industry: Agricultural Inputs

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NXTS
Nexentis Technologies Inc.
-0.13
5.23%
2.44 0.19 - 4.32 1.19 5.81 0.28
CTA-PB
E. I. du Pont de Nemours and Company
-
-%
56.50 - - 3.43 - - -
CTVA
Corteva Inc
0.10
0.80%
11.99 49.93 19.65 3.12 2.19 3.23 19.19
CTA-PA
E. I. du Pont de Nemours and Company
-0.96
2.08%
45.04 - - 2.71 - - -
NTR
Nutrien Ltd
0.64
0.90%
72.12 15.94 14.90 1.38 1.42 1.72 7.72

Profile*

Nexentis Technologies Inc.

Nexentis Technologies Inc., through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. It operates through two segments, Biotechnology Activity and Renewable Energy Projects. The company's pipeline includes MITOLINE, an algorithm used to perform multiple sequence/ structure pairwise alignments which could then be used for generating a 3D comparative model of potentially all mitochondrial carrier proteins; cloud-based computational chemistry platform; and novel in-vitro screening platforms; and advanced 3D NSCLC tumor spheroid systems.The company was formerly known as N2OFF, Inc. and changed its name to Nexentis Technologies Inc. in February 2026. Nexentis Technologies Inc. was incorporated in 2009 and is headquartered in Ness Ziona, Israel.

Pinhas Sapir St. 3, Ness Ziona, Israel, 7403626

972 347 468 9583

7

Name Title Year Born
Mr. David Palach Chief Executive Officer 1966
Ms. Lital Barda CFO, Financial Controller, Treasurer & Secretary 1987
Ms. Galit Kenigsberg Head of Sustainability Operations of scientific advisory board NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…